OTCMKTS:HKMPF - Hikma Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $21.10 0.00 (0.00 %) (As of 03/21/2019 03:10 PM ET)Previous Close$21.10Today's Range$21.10 - $21.1052-Week Range$12.00 - $26.3964Volume100 shsAverage Volume111 shsMarket Capitalization$5.08 billionP/E Ratio15.29Dividend YieldN/ABeta0.45 ProfileDiscussionAnalyst RatingsChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom. Receive HKMPF News and Ratings via Email Sign-up to receive the latest news and ratings for HKMPF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Private households Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:HKMPF Previous SymbolOTC:HKMPF CUSIPN/A CIKN/A Webwww.hikma.com Phone44-20-7399-2760Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E Ratio15.29 Forward P/E Ratio15.07 P/E Growth1.62 Sales & Book Value Annual Sales$2.07 billion Price / Sales2.46 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees8,500 Outstanding Shares240,870,000Market Cap$5.08 billion Next Earnings Date6/12/2019 (Estimated) OptionableNot Optionable Hikma Pharmaceuticals (OTCMKTS:HKMPF) Frequently Asked Questions What is Hikma Pharmaceuticals' stock symbol? Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF." When is Hikma Pharmaceuticals' next earnings date? Hikma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, June 12th 2019. View Earnings Estimates for Hikma Pharmaceuticals. What is the consensus analysts' recommendation for Hikma Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hikma Pharmaceuticals. Has Hikma Pharmaceuticals been receiving favorable news coverage? News headlines about HKMPF stock have been trending somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Hikma Pharmaceuticals earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. Who are some of Hikma Pharmaceuticals' key competitors? Some companies that are related to Hikma Pharmaceuticals include RENAULT S A/ADR (RNLSY), SUZUKI MTR CORP/ADR (SZKMY), KERRY GRP PLC/S (KRYAY), SGS (SGSOY), SECOM LTD/ADR (SOMLY), VESTAS WIND SYS/ADR (VWDRY), Deutsche Wohnen (DWHHF), FERROVIAL S A/ADR (FRRVY), OMV (OMVJF), KUEHNE & NAGEL/ADR (KHNGY), WILMAR INTL LTD/ADR (WLMIY), CARREFOUR SA/S (CRRFY), AGRICULTURAL BK/ADR (ACGBY), Fujitsu (FJTSY) and WIRECARD AG/ADR (WCAGY). What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include Hikma Pharmaceuticals (HIK), Tilray (TLRY), Suncor Energy (SU), Myriad Genetics (MYGN), Summit Wireless Technologies (WISA), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA), Bellerophon Therapeutics (BLPH), Titan Machinery (TITN) and Champions Oncology (CSBR). Who are Hikma Pharmaceuticals' key executives? Hikma Pharmaceuticals' management team includes the folowing people: Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 61)Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Hikma Pharmaceuticals' stock price today? One share of HKMPF stock can currently be purchased for approximately $21.10. How big of a company is Hikma Pharmaceuticals? Hikma Pharmaceuticals has a market capitalization of $5.08 billion and generates $2.07 billion in revenue each year. Hikma Pharmaceuticals employs 8,500 workers across the globe. What is Hikma Pharmaceuticals' official website? The official website for Hikma Pharmaceuticals is http://www.hikma.com. How can I contact Hikma Pharmaceuticals? Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company can be reached via phone at 44-20-7399-2760 or via email at [email protected] MarketBeat Community Rating for Hikma Pharmaceuticals (OTCMKTS HKMPF)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 85 (Vote Outperform)Underperform Votes: 109 (Vote Underperform)Total Votes: 194MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HKMPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HKMPF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: Trading Stocks - What are percentage gainers?